Drug Type Small molecule drug |
Synonyms Neramexane, Neramexane mesylate (USAN), KRP-209 + [2] |
Target |
Mechanism NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC12H27NO3S |
InChIKeyCLUKHUGGXSIGRX-UHFFFAOYSA-N |
CAS Registry457068-92-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05145 | Neramexane Mesylate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tinnitus | Phase 3 | AT | 01 Sep 2008 | |
Tinnitus | Phase 3 | DE | 01 Sep 2008 | |
Tinnitus | Phase 3 | PT | 01 Sep 2008 | |
Tinnitus | Phase 3 | ES | 01 Sep 2008 | |
Tinnitus | Phase 3 | GB | 01 Sep 2008 | |
Alzheimer Disease | Phase 3 | US | 01 Mar 2003 | |
Multiple Sclerosis | Phase 2 | GB | 01 May 2009 | |
X-Linked Infantile Nystagmus | Phase 2 | GB | 01 May 2008 | |
Alcoholism | Phase 2 | DE | - | |
Pain | Phase 2 | DE | - |
Not Applicable | - | - | Neramexane 0.9-7 mg/kg | dcwavyaecl(khfizleiql) = ljapzbzvms xqdelmwvhz (szfybeipdx ) | Positive | 12 Nov 2003 | |
joifeeomit(gxxtbvfoyc) = wtnpipubhb jkubkrzoss (fagpwdrylm ) |